<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="130278">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406015</url>
  </required_header>
  <id_info>
    <org_study_id>2009P-000311</org_study_id>
    <nct_id>NCT01406015</nct_id>
  </id_info>
  <brief_title>Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications</brief_title>
  <official_title>Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if spironolactone, a drug that blocks the action of
      aldosterone, can make the blood vessels work better in people with obesity. The
      investigators also want to find out whether spironolactone causes changes in levels of
      insulin and markers of inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brachial artery vascular reactivity</measure>
    <time_frame>6 weeks after respective treatments</time_frame>
    <description>Change in brachial artery vasodilatation in response to ischemia will be compared between treatment and placebo groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal plasma flow</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in renal plasma blood flow from baseline will be compared between the treatment and placebo groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>6 weeks</time_frame>
    <description>TNF alpha and MCP-1 will be measured as markers of inflammation. Changes in TNF alpha and MCP-1 from baseline will be compared between the treatment and placebo groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in insulin resistance from baseline will be compared between the treatment and placebo groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>50 mg daily for 6 weeks</description>
    <arm_group_label>Spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-70 years

          2. Good health as evidenced by history and physical exam

          3. BMI: &gt;30 kg/m2 and &lt;45 kg/m2

        Exclusion criteria:

          1. Medical illnesses other than treated hypothyroidism

          2. BP &gt;135/85 or systolic BP &lt;90 mm Hg

          3. Hepatic disease (transaminase &gt; 3 times normal)

          4. Renal impairment (Creatinine clearance &lt;60 ml/min)

          5. Baseline serum K &gt;5.0 mmol/L

          6. History of drug or alcohol abuse

          7. Allergies to spironolactone

          8. Participation in any other concurrent clinical trial

          9. Women using oral contraceptives within the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 12, 2013</lastchanged_date>
  <firstreceived_date>July 26, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Rajesh K. Garg</investigator_full_name>
    <investigator_title>Associate Physician</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Mineralocorticoid receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Mineralocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
